Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 16/20 | 0.50 |
| ▸ | SLC16A1 | P53985 | 16/20 | 0.50 |
| ▸ | MCTS1 | Q9ULC4 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3846803 | 0.90 | MAPT (0.46) | SLC16A3SLC16A1ALDH1A1TP53KDM4E | |
| SCHEMBL3849224 | 0.89 | ALDH1A1 (0.50) | ALDH1A1KDM4E | |
| SCHEMBL3851454 | 0.87 | ALDH1A1 (0.47) | SLC16A3SLC16A1MCTS1ALDH1A1TP53 | |
| SCHEMBL3853375 | 0.85 | ALDH1A1 (0.48) | SLC16A3SLC16A1MCTS1ALDH1A1KDM4E | |
| SCHEMBL3848738 | 0.84 | ALDH1A1 (0.46) | SLC16A3SLC16A1MCTS1ALDH1A1TP53 | |
| SCHEMBL3849133 | 0.83 | EGLN3 (0.51) | SLC16A3SLC16A1MCTS1TP53 | |
| SCHEMBL3853108 | 0.83 | SLC16A3 (0.45) | SLC16A3SLC16A1MCTS1ALDH1A1TP53 | |
| SCHEMBL3849543 | 0.83 | ALDH1A1 (0.47) | SLC16A3SLC16A1MCTS1ALDH1A1TP53 | |
| SCHEMBL3847935 | 0.83 | ALDH1A1 (0.46) | SLC16A3SLC16A1ALDH1A1TP53KDM4E | |
| SCHEMBL3847266 | 0.82 | EGLN3 (0.51) | SLC16A3SLC16A1MCTS1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2889289-A1 | Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors | GlaxoSmithKline LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-RE44613-E1 | N-substituted glycine derivatives: hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-7608621-B2 | Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production | SMITHKLINE BEECHAM, CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | EGLN2, EGLN3, HIF1AN | SLC16A3 766/4885SLC16A1 480/4885MCTS1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.